Key Points
- Tempus AI CEO Eric Lefkofsky sold 22,335 shares on May 19 at an average price of $44.07, totaling about $984,303. The filing said the sale was made to cover tax withholding obligations tied to vested equity awards.
- After the transaction, Lefkofsky still directly owned 2.23 million shares worth roughly $98.3 million, reflecting a modest 0.99% reduction in his stake.
- Tempus AI recently reported better-than-expected quarterly results, with EPS of -$0.13 versus -$0.21 expected and revenue of $348.1 million, up 36.1% year over year. Analysts currently rate the stock a Moderate Buy with an average price target of $68.64.
Tempus AI, Inc. (NASDAQ:TEM - Get Free Report) CAO Ryan Bartolucci sold 4,116 shares of the stock in a transaction that occurred on Tuesday, May 19th. The stock was sold at an average price of $44.07, for a total value of $181,392.12. Following the completion of the sale, the chief accounting officer owned 74,041 shares in the company, valued at approximately $3,262,986.87. The trade was a 5.27% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Tempus AI Price Performance
TEM opened at $46.49 on Friday. The business has a fifty day moving average of $49.02 and a 200 day moving average of $59.39. The stock has a market cap of $8.35 billion, a P/E ratio of -27.03 and a beta of 3.99. The company has a quick ratio of 3.15, a current ratio of 3.31 and a debt-to-equity ratio of 2.96. Tempus AI, Inc. has a 52-week low of $41.73 and a 52-week high of $104.32.
Tempus AI (NASDAQ:TEM - Get Free Report) last released its earnings results on Tuesday, May 5th. The company reported ($0.13) earnings per share for the quarter, topping analysts' consensus estimates of ($0.21) by $0.08. Tempus AI had a negative return on equity of 53.83% and a negative net margin of 22.20%.The business had revenue of $348.12 million for the quarter, compared to analyst estimates of $345.44 million. During the same quarter last year, the firm posted ($0.24) earnings per share. The business's revenue was up 36.1% compared to the same quarter last year. As a group, sell-side analysts anticipate that Tempus AI, Inc. will post -1.35 EPS for the current year.
Analyst Ratings Changes
A number of equities research analysts recently weighed in on the stock. Morgan Stanley decreased their price objective on shares of Tempus AI from $85.00 to $70.00 and set an "overweight" rating for the company in a report on Tuesday, March 3rd. Jefferies Financial Group started coverage on shares of Tempus AI in a research report on Monday, April 13th. They set an "underperform" rating and a $35.00 target price on the stock. HC Wainwright lowered their price target on Tempus AI from $95.00 to $64.00 and set a "buy" rating for the company in a report on Monday, May 11th. BTIG Research dropped their price objective on Tempus AI from $90.00 to $80.00 and set a "buy" rating on the stock in a research note on Friday, May 8th. Finally, Needham & Company LLC restated a "buy" rating and set a $75.00 price objective on shares of Tempus AI in a report on Wednesday, March 11th. Nine analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $68.64.
Get Our Latest Research Report on Tempus AI
Institutional Inflows and Outflows
A number of institutional investors have recently added to or reduced their stakes in the business. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Tempus AI by 1,459.8% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 101,276 shares of the company's stock worth $8,174,000 after acquiring an additional 94,783 shares in the last quarter. Vanguard Group Inc. boosted its position in Tempus AI by 22.1% during the third quarter. Vanguard Group Inc. now owns 9,441,607 shares of the company's stock valued at $762,032,000 after purchasing an additional 1,706,837 shares in the last quarter. Hussman Strategic Advisors Inc. purchased a new position in Tempus AI in the third quarter valued at about $1,695,000. Krane Funds Advisors LLC grew its stake in Tempus AI by 218.2% in the third quarter. Krane Funds Advisors LLC now owns 28,230 shares of the company's stock valued at $2,427,000 after purchasing an additional 19,358 shares during the last quarter. Finally, Aberdeen Group plc raised its holdings in Tempus AI by 64.2% in the fourth quarter. Aberdeen Group plc now owns 263,004 shares of the company's stock worth $15,530,000 after purchasing an additional 102,878 shares in the last quarter. Hedge funds and other institutional investors own 24.22% of the company's stock.
About Tempus AI
(
Get Free Report)
Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.
The company's core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
